Analyst Ratings For Ovid Therapeutics (NASDAQ:OVID)
Today, Piper Jaffray Companies initiated coverage on Ovid Therapeutics (NASDAQ:OVID) with a Overweight with a price target of $20.00.
Some recent analyst ratings include
- 3/9/2018-Piper Jaffray Companies initiated coverage with a Overweight rating.
- 5/30/2017-Citigroup initiated coverage with a Buy rating.
- 5/30/2017-William Blair initiated coverage with a Outperform rating.
- 5/30/2017-JMP Securities initiated coverage with a Mkt Outperform rating.
- 5/30/2017-Cowen initiated coverage with a Outperform rating.
- On 8/25/2017 Jeremy M Levin, CEO, bought 15,334 with an average share price of $7.15 per share and the total transaction amounting to $109,638.10.
Recent Trading Activity for Ovid Therapeutics (NASDAQ:OVID)
Shares of Ovid Therapeutics closed the previous trading session at 8.29 up +0.29 3.62% with 8.539999961853027 shares trading hands.